You are here

Home » Content

DisHpidemik hastalarda 4 haftalık kısa dönem günde tek doz 200 mg mikronize fenofibrat tedavisinin etkinlik ve güvenilirliği

Efficacy and Tolerability of Micronised Fenofibrat, in Dyslipidemic Patients.

Journal Name:

  • Süleyman Demirel Üniversitesi Tıp Fakültesi Dergisi

Publication Year:

  • 2004

Key Words:

Keywords (Original Language):

Author NameUniversity of AuthorFaculty of Author
Abstract (2. Language): 
This study was conducted to evaluate the efficacy and safety of micronised fenofibrat 200 mg single-dose in dyslipidemic patients. It was an open study without a control group. Fourteen patients (range: 26 to 62 years; mean age: 44,9 10,5 years) in type IIa dyslipidemic group, 26 patients (range: 26 to 51 years; mean age: 40,5 7,4 years) in type IIb group and 6 patients (range: 24 to 57 years; mean age: 42 10,8 years) in type IV group includ¬ed in the study. 200 mg once-daily dose of micronised fenofibrat was given to patients after a four weeks stan¬dart diet without drug. Efficacy and safety parameters were assessed. After a four weeks short term treatment period, group type IIa showed a decrease of 17% in total cholesterol (TC), 22% in low density lipoprotein cholesterol (LDL-C), 28% in triglyceride (TG) and an increase of 18% in high density lipoprotein cholesterol (HDL-C) level. Type IIb dyslipidemic group showed a decrease of 14% in TC, 8% in LDL-C, 42% in TG and increase of 22% in HDL-C. All lipid variations were found statistically sig¬nificant (p = 0,001 and p < 0,001). Statistical analysis was not performed due to insufficient number in type IV group. No significant difference were detected in safety parameters (creatine kinaz, liver function tests, blood counts). No major side effect was observed. It was concluded that micronised fenofibrat is an effective and safe alternative for treatment of type IIa and IIb dyslipidemia.
Bookmark/Search this post with
Abstract (Original Language): 
Bu çalışma günde tek doz mikronize fenofibratın etkinlik ve güvenilirliğini araştırmak amacıyla yapıldı. Açık kontrol grubu olmayan bir çalışmadır. Çalışmaya tip IIa dislipidemi grubundan 14 (yaş aralığı: 26-62; yaş ortalaması: 44, 9 10,5) tip Iİb grubundan 26 (yaş aralığı: 26-51; yaş ortalaması: 40,5 7,4) ve tip IV grubundan 6 (yaş aralığı: 24-57; yaş ortalaması: 42 10,8) hasta alındı. Dört haftalık ilaçsız diyet tedavisi sonrası, dört hafta boyun¬ca günde tek doz 200 mg mikronize fenofibrat verildi. Etkinlik ve güvenilirlik parametreleri değerlendirildi. Dört haftalık kısa dönem tedavi sonunda tip IIa gubunda total kolesterol'de (TK) %17, düşük dansiteli lipoprotein kolesterol'de (LDL-K) %22, trigliserid'de (TG) %28 azalma ve yüksek dansiteli lipoprotein kolesterolde (HDL-K) ise %18 lik artış tespit edildi. Tip IIb grubunda ise TK'de %14 , LDL-K'de %8, TG vde %42 azalma ve HDL-K' de %22 lik artma tesbit edildi. Her iki gruptaki lipid değerlerindeki değişim istatistiksel açıdan anlam¬lı bulundu ( p = 0,001 ve p < 0,001). Tip IV grubunda sayı az olduğundan istatistik yapılmadı. Güvenilirlik parametrelerinde (kreatinine kinaz, karaciğer fonksiyon testleri, kan sayımı) anlamlı değişiklik saptanmadı. Önemli yan etki gözlenmedi. Mikronize fenofibratın tip IIa ve tip IIb dislipidemilerinde etkin ve güvenilir bir tedavi seçeneği olduğu kanısına varıldı.
FULL TEXT (PDF): 
PDF icon arastirmax-dishpidemik-hastalarda-4-haftalik-kisa-donem-gunde-tek-doz-200-mg-mikronize-fenofibrat-tedavisinin-etkinlik-guvenilirligi.pdf
  • 3
12-15
  • Turkish

REFERENCES

References: 

1. Tikkanen M, Fibric acid derivatives. Curr Opin Lipidol 1992; 3: 29-33.
2.
Yükse
l H, Fibratlar ne zaman kullanılmalı? Türk Kardiyol Dern Arş 2001; 29: 715-22.
3. Vakkılainen J, Steiner G, Ansquer JC, et al. Relationsphips between Low - Density Lipoprotein particle size, plasma lipoproteins, and progression of coronary artery disease. Circulation 2003; 107: 1733-1737.
4. Adkins JC, Faulds D. Micronized fenofibrate; a review of its pharmacodynamic properties and clinical efficacy in the management of dyslipidemi. Drugs 1997; 54: 615-33.
5. Expert Panel on Detection Evaluation and Treatment of High Blood Cholesterol in Adults. Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP). Expert Panel on Dedection, Evaluation and Treatment of High Blood Cholesterol in Adults. (Adult Treatment Panel III). JAMA 2001 May 16; 285: 2486-97.
6. Gordon DJ, Probstfield JL, Garrison RJ et al. High density lipoprotein cholesterol and cardiovascular disease: four prospective American studies. Circulation 1989; 79: 8-15.
7. Onat A: Risk factors for cardiovascular disease in Turkey. Atherosclerosis 2001; 156: 1-10.
8. Mahley RW, Daloğlu E, Atak Z. et al: Turkish Heart Study: Lipids, lipoproteins and apolipoproteins J Lipid Res 1995;
36: 839-59.
9. Malmendier C, Deicroix C. Effects of fenofibrate on high and low density lipoprotein metabolism in heterozygous familial hypercholesterolemia. Atherosclerosis 1985; 55:
161-69.
10. Fruchart JC, Brewer HB, Leitersdorf E. Consensus for the use of fibrates in the treatment of dyslipoproteinemia and coronary heart disease Am J Cardiol 1998; 81: 912-17.
11. Goldberg AC, Schonfeld G, Feldman EB, et al. Fenofibrate for the treatment of type IV and V hyperlipoproteinemias: a double blind, placebo controlled multicenter US study. Clin Ther 1989; 11: 69-83.
12. Europeen Atherosclerosis Society: The recognition and management of hyperlipidemia in adults: a policy statement of the European Atherosclerosis Society. Eur Heart J 1988; 9: 571-600.
13. Kirschgassler KU, Schmitz H, Bach G. Effectiveness and
tolerability of 12 week treatment with micronised fenofi-brate, 200 mg in drug monitoring programme involving 9884 patients with dyslipidemia. Clin Drug Invest 1998; 15: 197-204.
14. Tokgözoğlu L, Yüksel H. Bir Türk kohortundaki dislipi-demik hastalarda 12 hafta süreli günde tek doz 200 mg mikronize fenofibrat ile tedavinin etkinlik ve güvenilirliği.
Türk
Kardiyo
l Dern Arş 2003; 31: 74-81.

Thank you for copying data from http://www.arastirmax.com